Genprex, Inc.
GNPXHealthcare|Biotechnology|US
$2.07
-0.03 (-1.43%)
DCF Value
$168.10
Tangible Book / Share
$31.27
Cash / Share
$32.03
Financials
Financial Snapshot
Market Cap
$1.0M
Enterprise Value
-$14.1M
Revenue (TTM)
$0.00
Net Income (TTM)
-$16.5M
Cash & Investments
$15.2M
Net Cash
$15.2M
Free Cash Flow (TTM)
-$15.6M
Operating CF (TTM)
-$15.6M
Debt/Equity
0.00
Cash Runway & Burn Rate
Cash on Hand
$15.2M
Quarterly Burn
$3.9M
Monthly Burn
$1.3M
Est. Runway
~3.9 quarters
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Investments | $1.6M | $161.3K | $8.6M | $2.0M | $27.3M | $38.6M | $21.0M | $6.7M | $1.6M | $7.8M | $15.2M | |
| Operating Cash Flow | -$1.2M | -$2.2M | -$6.8M | -$6.9M | -$13.9M | -$14.3M | -$17.8M | -$24.7M | -$17.1M | -$15.3M | -$15.6M | |
| Free Cash Flow | -$1.3M | -$2.2M | -$6.9M | -$7.9M | -$16.3M | -$14.4M | -$17.8M | -$24.8M | -$17.1M | -$15.3M | -$15.6M | |
| Capital Expenditure | -$89.5K | -$63.4K | -$103.3K | -$946.9K | -$2.3M | -$83.8K | $4.00 | -$71.4K | $0.00 | -$1.00 | $5.00 | |
| Financing Cash Flow | $2.7M | $794.0K | $15.4M | $1.3M | $41.6M | $25.7M | $6.4K | $10.6M | $12.0M | $21.5M | $29.4M |
R&D Spending
R&D (TTM)
$9.8M
R&D Intensity
—
R&D Growth vs Prior
+4.1%
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| R&D Expense | $354.9K | $289.9K | $971.4K | $2.0M | $7.3M | $9.0M | $11.5M | $17.6M | $10.5M | $9.4M | $9.8M | |
| SG&A | $3.8M | $3.0M | $11.4M | $8.7M | $10.6M | $11.7M | $12.3M | $13.4M | $10.6M | $6.1M | $6.0M |
Income Statement
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Cost of Revenue | $0.00 | $0.00 | $5.9K | $13.1K | $22.8K | $22.5K | $25.6K | $15.0K | $6.7K | $0.00 | $0.00 | |
| Gross Profit | $0.00 | $0.00 | -$5.9K | -$13.1K | -$22.8K | -$22.5K | -$25.6K | -$15.0K | -$6.7K | $0.00 | $0.00 | |
| R&D | $354.9K | $289.9K | $971.4K | $2.0M | $7.3M | $9.0M | $11.5M | $17.6M | $10.5M | $9.4M | $9.8M | |
| SG&A | $3.8M | $3.0M | $11.4M | $8.7M | $10.6M | $11.7M | $12.3M | $13.4M | $10.6M | $6.1M | $6.0M | |
| Operating Income | -$4.1M | -$3.3M | -$12.4M | -$10.7M | -$18.0M | -$20.7M | -$23.8M | -$31.1M | -$21.2M | -$15.5M | -$15.8M | |
| Interest Expense | $0.00 | $1.9K | $38.0K | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $739.9K | $455.5K | |
| Pretax Income | -$4.1M | -$3.3M | -$12.4M | -$10.7M | -$17.9M | -$20.7M | -$23.7M | -$30.9M | -$21.1M | -$16.2M | -$16.5M | |
| Net Income | -$4.1M | -$3.3M | -$12.4M | -$10.7M | -$17.9M | -$20.7M | -$23.7M | -$30.9M | -$21.1M | -$16.2M | -$16.5M | |
| EPS (Diluted) | -16786.00 | -12683.00 | -39534.00 | -29249.00 | -22198.00 | -19305.00 | -21780.00 | -24816.00 | -5872.98 | -382.80 | -158.78 | |
| EBITDA | -$4.1M | -$3.3M | -$12.3M | -$10.6M | -$17.9M | -$20.6M | -$23.7M | -$30.8M | -$21.1M | -$15.5M | -$15.8M | |
| Shares Out. (M) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.04 | 0.47 |
Balance Sheet
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $1.6M | $161.3K | $8.6M | $2.0M | $27.3M | $38.6M | $21.0M | $6.7M | $1.6M | $7.8M | $15.2M | |
| Short-Term Investments | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Total Current Assets | $1.6M | $193.6K | $8.8M | $3.0M | $30.7M | $39.1M | $21.5M | $7.5M | $2.1M | $8.4M | $15.8M | |
| Total Assets | $1.9M | $1.3M | $9.3M | $3.5M | $31.4M | $42.9M | $25.1M | $10.7M | $4.1M | $10.2M | $17.1M | |
| Total Current Liabilities | $285.7K | $831.0K | $387.8K | $510.7K | $450.7K | $1.6M | $2.8M | $3.3M | $2.5M | $2.2M | $2.3M | |
| Long-Term Debt | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Total Liabilities | $285.7K | $831.0K | $387.8K | $510.7K | $450.7K | $1.6M | $2.8M | $3.3M | $2.5M | $2.2M | $2.3M | |
| Stockholders' Equity | $1.6M | $428.6K | $8.9M | $3.0M | $30.9M | $41.3M | $22.3M | $7.4M | $1.6M | $8.0M | $14.8M | |
| Retained Earnings | -$14.1M | -$17.5M | -$29.8M | -$40.5M | -$58.4M | -$79.1M | -$102.8M | -$133.7M | -$154.8M | -$171.0M | -$179.9M |
Cash Flow Statement
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$1.2M | -$2.2M | -$6.8M | -$6.9M | -$13.9M | -$14.3M | -$17.8M | -$24.7M | -$17.1M | -$15.3M | -$15.6M | |
| Capital Expenditure | -$89.5K | -$63.4K | -$103.3K | -$946.9K | -$2.3M | -$83.8K | $4.00 | -$71.4K | $0.00 | -$1.00 | $5.00 | |
| Free Cash Flow | -$1.3M | -$2.2M | -$6.9M | -$7.9M | -$16.3M | -$14.4M | -$17.8M | -$24.8M | -$17.1M | -$15.3M | -$15.6M | |
| Investing Cash Flow | -$89.5K | -$63.4K | -$103.3K | -$946.9K | -$2.3M | -$83.8K | $97.7K | -$71.2K | $1.2K | $0.00 | $0.00 | |
| Financing Cash Flow | $2.7M | $794.0K | $15.4M | $1.3M | $41.6M | $25.7M | $6.4K | $10.6M | $12.0M | $21.5M | $29.4M | |
| Issuance of Stock | $2.7M | $794.0K | $15.4M | $1.3M | $41.6M | $25.7M | $6.4K | $10.6M | $12.0M | $21.5M | $29.4M | |
| Repurchase of Stock | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Net Debt Issuance | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Stock Based Comp. | $2.7M | $1.3M | $5.4M | $3.5M | $4.2M | $5.3M | $4.7M | $5.4M | $3.3M | $312.8K | $107.0K | |
| Net Change in Cash | $1.4M | -$1.4M | $8.4M | -$6.6M | $25.3M | $11.3M | -$17.7M | -$14.2M | -$5.1M | $6.2M | $13.8M |
Dilution Tracker
Shares outstanding grew 5153.7% over 5 years — significant dilution
Shares Outstanding
1M
5-Year Share Growth
+5153.7%
Stock Issuance (TTM)
$29.4M
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Shares Out. (M) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.04 | 0.47 | |
| Change vs Prior % | — | 6.1% | 19.9% | 16.3% | 121.7% | 32.6% | 1.9% | 14.0% | 193.0% | 1064.1% | 1016.0% | |
| Stock Issuance | $2.7M | $794.0K | $15.4M | $1.3M | $41.6M | $25.7M | $6.4K | $10.6M | $12.0M | $21.5M | $29.4M | |
| Stock Repurchase | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Stock Based Comp. | $2.7M | $1.3M | $5.4M | $3.5M | $4.2M | $5.3M | $4.7M | $5.4M | $3.3M | $312.8K | $107.0K |
Margins & Profitability
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE % | -254.3% | -773.3% | -139.3% | -352.4% | -58.0% | -50.1% | -106.6% | -416.1% | -1303.0% | -203.8% | -163.1% | |
| ROA % | -216.3% | -263.1% | -133.5% | -301.5% | -57.2% | -48.2% | -94.6% | -289.2% | -511.9% | -159.7% | -96.3% | |
| ROIC % | -254.3% | -772.9% | -139.2% | -353.3% | -58.1% | -50.1% | -107.0% | -419.0% | -1306.9% | -194.3% | -107.1% |
Growth (Year over Year)
Fiscal years. Rising share count growth means dilution.
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Gross Profit | 0.0% | 0.0% | 0.0% | -122.1% | -74.3% | 1.1% | -13.5% | 41.3% | 55.4% | 100.0% | |
| Operating Income | -286.3% | 19.8% | -273.3% | 13.6% | -68.1% | -15.1% | -15.3% | -30.4% | 31.9% | 26.7% | |
| Net Income | -286.3% | 19.8% | -273.3% | 13.9% | -68.4% | -15.2% | -14.9% | -30.0% | 31.6% | 23.1% | |
| EPS (Diluted) | 33.4% | 24.4% | -211.7% | 26.0% | 24.1% | 13.0% | -12.8% | -13.9% | 76.3% | 93.5% | |
| Operating Cash Flow | -81.4% | -74.0% | -215.3% | -1.1% | -101.4% | -2.5% | -24.5% | -39.1% | 30.7% | 10.7% | |
| Free Cash Flow | -88.5% | -67.1% | -211.0% | -13.2% | -106.9% | 11.7% | -23.7% | -39.5% | 30.9% | 10.7% | |
| R&D Expense | 75.7% | -18.3% | 235.1% | 102.5% | 271.3% | 22.8% | 28.3% | 53.1% | -40.2% | -10.5% | |
| SG&A Expense | 336.2% | -20.1% | 277.1% | -23.6% | 22.2% | 9.8% | 5.3% | 9.3% | -20.9% | -42.7% | |
| Total Assets | 365.9% | -34.1% | 635.9% | -61.9% | 787.5% | 36.6% | -41.5% | -57.5% | -61.3% | 146.3% | |
| Book Value / Share | -29.3% | -75.2% | 1628.0% | -70.7% | 361.2% | 0.7% | -47.0% | -70.8% | -92.5% | -57.8% | |
| Debt | 0.0% | 0.0% | -54.1% | -100.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Diluted Shares | 485.7% | 6.1% | 19.9% | 16.3% | 121.7% | 32.6% | 1.9% | 14.0% | 193.0% | 1064.1% |
Valuation
P/E (TTM)At Loss
P/S0.00
P/B0.07
10Y Low / Med / High0.21 / 2.11 / 125.94
EV/EBITDA0.90
EV/Revenue0.00
P/FCFAt Loss
Intrinsic Value Models (per share)
DCF Value
$168.10
Tangible Book / Share
$31.27
Net Current Assets / Share
$26.74
Graham Net-Net
$27.08
Cash / Share
$32.03
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P/E Ratio | -12.29 | -16.28 | -1.22 | -0.48 | -8.23 | -2.99 | -2.93 | -0.41 | -0.16 | -0.10 | -0.01 | |
| P/S Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| P/B Ratio | 31.18 | 125.94 | 1.71 | 1.70 | 4.77 | 1.49 | 3.12 | 1.70 | 2.11 | 0.21 | 0.07 | |
| EV/EBITDA | -11.88 | -16.32 | -0.54 | -0.29 | -6.70 | -1.12 | -2.05 | -0.19 | -0.09 | 0.40 | 0.90 | |
| EV/Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Analyst Estimates & Quality
Altman Z-Score
-16.52
Distress
Piotroski F-Score
2
Weak
Forward Estimates (consensus)
| Metric | FY2026 | FY2027 | FY2028 |
|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 |
| Net Income | -$53.6M | -$447.7M | -$457.9K |
| EPS | $-1265.00 | $-10560.00 | $-10.80 |
| # Analysts (EPS) | 1 | 1 | 1 |